RecruitingNCT06727370

Cognitive Screening in Lung Cancer Patients


Sponsor

European Institute of Oncology

Enrollment

200 participants

Start Date

Jan 10, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is screening people with lung cancer for cognitive (thinking and memory) difficulties, which can sometimes be an under-recognized side effect of the disease or its treatment. The goal is to understand how common these problems are and find them early. **You may be eligible if...** - You have been diagnosed with small-cell or non-small-cell lung cancer (any stage I-IV) - You are 18 years of age or older (but under 70) - You can speak and read the local language fluently - You are willing to give informed consent **You may NOT be eligible if...** - You are 70 years of age or older - You have cancer that has spread to the brain (brain metastases) - You have a pre-existing neurological or psychiatric condition - You are currently receiving radiation to the brain - You have had a previous lung cancer diagnosis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Istituto Europeo di Oncologia

Milan, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06727370


Related Trials